↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Bjorck P) "

Search: WFRF:(Bjorck P)

Result 1-10 of 44

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Kehoe, Laura, et al. (author) Make EU trade with Brazil sustainable 2019 In: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 364:6438, s. 341- Journal article (other academic/artistic)
2.	Ahmed, O, et al. (author) Statins regulate PNPLA3 through a mechanism that requires SREBF2 in human liver cells 2023 In: JOURNAL OF HEPATOLOGY. - 0168-8278. ; 78, s. S756-S757 Conference paper (other academic/artistic)
3.	Alping, P., et al. (author) Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients 2016 In: Annals of Neurology. - : Wiley. - 0364-5134 .- 1531-8249. ; 79:6, s. 950-958 Journal article (peer-reviewed)abstract Objective: Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients who are stable on natalizumab switch to other therapies to avoid progressive multifocal leukoencephalopathy. Methods: We compared outcomes for all RRMS patients switching from natalizumab due to JC virus antibody positivity at 3 Swedish multiple sclerosis centers with different preferential use of rituximab and fingolimod (Stockholm, n = 156, fingolimod 51%; Gothenburg, n = 64, fingolimod 88%; Umea, n = 36, fingolimod 19%), yielding a total cohort of N = 256 (fingolimod 55%). Results: Within 1.5 years of cessation of natalizumab, 1.8% (rituximab) and 17.6% (fingolimod) of patients experienced a clinical relapse (hazard ratio for rituximab = 0.10, 95% confidence interval [CI] = 0.02-0.43). The hazard ratio (favoring rituximab) for adverse events (5.3% vs 21.1%) and treatment discontinuation (1.8% vs 28.2%) were 0.25 (95% CI = 0.10-0.59) and 0.07 (95% CI = 0.02-0.30), respectively. Furthermore, contrast-enhancing lesions were found in 1.4% (rituximab) versus 24.2% (fingolimod) of magnetic resonance imaging examinations (odds ratio = 0.05, 95% CI = 0.00-0.22). Differences remained when adjusting for possible confounders (age, sex, disability status, time on natalizumab, washout time, follow-up time, and study center). Interpretation: Our findings suggest an improved effectiveness and tolerability of rituximab compared with fingolimod in stable RRMS patients who switch from natalizumab due to JC virus antibody positivity. Although residual confounding factors cannot be ruled out, the shared reason for switching from natalizumab and the preferential use of either rituximab or fingolimod in 2 of the centers mitigates these concerns.
4.	Hammareus, F, et al. (author) Hemodynamics and plasma biomarkers in individuals with mild-to-moderate ascending aortic dilatation and tricuspid aortic valves 2023 In: EUROPEAN HEART JOURNAL. - 0195-668X. ; 44 Conference paper (other academic/artistic)
5.	Islam-Jakobsson, P., et al. (author) Rituximab in multiple sclerosis, a long term safety and efficacy study 2015 In: Multiple Sclerosis Journal. - 1352-4585 .- 1477-0970. ; 21, s. 574-574 Journal article (other academic/artistic)
6.	Ivanova, N, et al. (author) Hereditary spastic paraplegia 3A associated with axonal neuropathy 2007 In: Archives of neurology. - : American Medical Association (AMA). - 0003-9942. ; 64:5, s. 706-713 Journal article (peer-reviewed)
7.	Lindstrand, A, et al. (author) Integration of genome sequencing into health care - experiences from 3211 rare disease patients show high diagnostic rates across multiple clinical entities 2020 In: EUROPEAN JOURNAL OF HUMAN GENETICS. - : SPRINGERNATURE. - 1018-4813 .- 1476-5438. ; 28:SUPPL 1, s. 52-53 Conference paper (other academic/artistic)
8.	Smith, FJD, et al. (author) The genetic basis of pachyonychia congenita 2005 In: The journal of investigative dermatology. Symposium proceedings. - : Elsevier BV. - 1087-0024. ; 10:1, s. 21-30 Journal article (peer-reviewed)
9.	Ahvenainen, T, et al. (author) Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer 2008 In: Cancer genetics and cytogenetics. - : Elsevier BV. - 1873-4456 .- 0165-4608. ; 183:2, s. 83-88 Journal article (peer-reviewed)
10.	Bhattachariya, A, et al. (author) Role of non-coding RNAs in thoracic aortic aneurysm associated with bicuspid aortic valve 2016 In: CARDIOVASCULAR RESEARCH. - 0008-6363. ; 111, s. S104-S104 Conference paper (other academic/artistic)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-10 of 44

Refine your search

Type of publication: journal article (27); conference paper (16); book chapter (1)

Type of content: other academic/artistic (22); peer-reviewed (22)

Author/Editor: Eriksson, P (21); Franco-Cereceda, A (17); Bjorck, E (11); Maleki, S (8); Du, L (6); Olsson, C (6); show more...; Bjorck, H (6); Lang, K. (4); Bergman, O (4); Mattsson, P (4); Nordenskjold, M (3); Gustavsson, P (3); Lundstromer, K (3); Evangelista, A. (2); Zedenius, J (2); Svensson, M. (2); Aaltonen, LA (2); Vahteristo, P (2); Piehl, F (2); Nordgren, A (2); Grigelioniene, G (2); Nilsson, D (2); Bjorck, A (2); Paulie, S (2); Pettersson, M. (2); Aittomaki, K (2); Lehtonen, R (2); Herva, R (2); Hietala, M (2); Vierimaa, O (2); Launonen, V (2); Svenningsson, Anders (2); Lindstrand, A (2); Malmgren, H (2); Alping, P (2); Fink, K (2); Frisell, T (2); Salzer, Jonatan (2); Islam-Jakobsson, P. (2); Kvarnung, M (2); Andelfinger, G (2); Wincent, J (2); Tham, E. (2); Lagerstedt-Robinson, ... (2); Kostareva, A (2); Tesi, B (2); Alaerts, M (2); Hammarsjo, A (2); Lagerstedt, K (2); Bhattachariya, A (2); show less...

University: Karolinska Institutet (41); Uppsala University (4); Royal Institute of Technology (3); University of Gothenburg (2); Umeå University (2); Lund University (2); show more...; Stockholm University (1); University of Gävle (1); Mid Sweden University (1); Chalmers University of Technology (1); Swedish University of Agricultural Sciences (1); show less...

Language: English (44)

Research subject (UKÄ/SCB): Medical and Health Sciences (8); Natural sciences (1); Engineering and Technology (1); Social Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view